AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02555709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Placebo 1 matching VTP-43742 administered as an oral capsule once daily
Study NCT02555709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2
Description: Placebo 2 matching VTP-43742 administered as an oral capsule once daily
Study NCT00219856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: * Induction : intravenous propofol aiming a concentration of 4 to 8 µg/ml~* Maintenance : intravenous propofol aiming a concentration of 3 to 6 µg/ml
Study NCT00219856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penthotal
Description: Intravenous penthotal at the dose of 3 to 5 mg/kg
Study NCT00219856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Inhaled desflurane aiming an alveolar concentration of 4 to 6 per cent.
Study NCT02999165 — intervention group
Intervention type: OTHER
Intervention: Nasogastric feeding
Description: The control intervention is feeding via nasogastric tube
Study NCT01454583 — intervention group
Intervention type: DRUG
Intervention: Aliskiren
Description: Aliskiren (Rasilez®, Novartis) is the first clinically available substance with direct renin inhibition (DRI) which effectively lowers blood pressure.
Study NCT01454583 — intervention group
Intervention type: DRUG
Intervention: ACE-I/ARB
Study NCT01454583 — intervention group
Intervention type: DRUG
Intervention: No RAS-inhibition
Study NCT01044004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Armodafinil 150 mg/day for 13 weeks
Study NCT01044004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo 150mg/day for 13 weeks
Study NCT02491671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Study NCT02491671 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard preventive measures
Study NCT02491671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard preventive measures
Study NCT04369092 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DYMUS
Description: DYsphagia in MUltiple Sclerosis (DYMUS) that was questionnare and Eating Assessment Tool (EAT-10) were used for assess swallowing problem. All individuals were classified according to DYMUS. The DYMUS Score was 1 or 2 was taken as mild swallowing problems, 3 or more was taken as severe swallowing problems. Patients were divided into three groups; first group that include patients without swallowing problems, second group that include patients with mild swallowing problems, third group that include severe swallowing problems.
Study NCT02444455 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMSC group
Description: Human umbilical cord MSCs are transplanted by intravenous infusion(5×10\^5/kg) once a day,a total of three times.
Study NCT01398488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: Patient education by health care professional compared to education via tablet PC
Study NCT01398488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Patient education by health care professional compared to education via tablet PC
Study NCT02368249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Patients are receiving a post-operative intravenous terlipressin treatment in association with human albumin to preserve the renal function
Study NCT02368249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients are receiving a post-operative intravenous Ringer's lactate solution
Study NCT04282135 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MCC IMS
Description: Diagnosis by MCC IMS
Study NCT02006147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC399
Description: Dose-escalation Study from 100 mM PL (20 µL) with 0.24 mg DSP to 100 mM PL (20 µL) with0.36 mg DSP to 100 mM PL (20 µL) with 0.6 mg DSP to 50 mM PL (10 µL) with 0.6 mg DSP.
Study NCT02558010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Perioperative IV methadone to be given
Study NCT02558010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: control arm
Study NCT02558010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Both groups will receive morphine via Patient-Controlled Analgesia (PCA) pump.
Study NCT02558010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Both groups will receive morphine via Patient-Controlled Analgesia (PCA) pump.
Study NCT02380833 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MyPlate
Description: To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations for eight weeks.
Study NCT03070613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescent Lectin Application
Description: Fluorescein conjugated wisteria floribunda (a lectin).
Study NCT04647149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Approach
Description: Dietary approaches with energy restriction performed at different times of the day.
Study NCT02293538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FID 114657 eye drops (10 ml)
Description: Lubricating eye drop for temporary relief of burning and irritation due to dryness of the eye
Study NCT02293538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline control eye drops (15 ml)
Description: Saline eye drops (15 ml)
Study NCT02380833 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MyPlate + Exercise
Description: To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
Study NCT02380833 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paleolithic
Description: To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations for eight weeks.
Study NCT02380833 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paleolithic + Exercise
Description: To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
Study NCT02155283 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Passive Motion
Description: Daily self-treatments at home for 3 weeks, with up to three 10-minute treatment sessions per day
Study NCT02923453 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CNT 2000 American ginseng extract
Study NCT00539539 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laerdal Q-CPR /technology
Description: For the first three to six months, participating EMS agencies will have defibrillators with automated, real-time feedback inactivated. During this period, the baseline rate of ROSC (and secondary outcomes) will be collected. At the end of this baseline period, EMS agencies will be randomized to one of two interventions, with randomization stratified within site by agency, station, or device. All clusters will cross-over to the opposite feedback strategy at least once during the intervention phase.
Study NCT02923453 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04370171 — intervention group
Intervention type: OTHER
Intervention: care modalities
Description: For these patients the consultation has been postponed for 6 months. No specific intervention for this group of patient.
Study NCT04370171 — intervention group
Intervention type: OTHER
Intervention: Teleconsultation either by phone or by computer consultation
Description: Management of diabetic patients by telemedicine with a teleconsultation either by phone or by computer consultation
Study NCT02594033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: All subjects make three intervention visits with at least 5 days between individual intervention visits. At each intervention visit the subject receives one insulin aspart injection with only one type of needle.
Study NCT02594033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: All subjects make three intervention visits with at least 5 days between individual intervention visits. At each intervention visit the subject receives one insulin aspart injection with only one type of needle.
Study NCT02293538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habitual contact lenses
Description: Commercially marketed biweekly or monthly replacement soft contact lenses as prescribed by eye care practitioner, brand and power
Study NCT02293538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual contact lenses
Description: Commercially marketed biweekly or monthly replacement soft contact lenses as prescribed by eye care practitioner, brand and power
Study NCT04401384 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Diclectin
Description: Diclectin (combination of 10 mg doxylamine and 10 mg pyridoxine hydrochloride in a delayed release tablet) During the first two days, patients will start with an initial oral dose of 2 tablets at bedtime. If the symptoms assessed on the second day are not relieved, 3 tablets will be administered on the third day (1 tablet in the morning and 2 tablets at bedtime). On the third day if the symptoms are still not relieved, another tablet will be added in the afternoon on the fourth day (1 tablet in the morning, 1 tablet in the afternoon and 2 tablets at bedtime). Therefore, the maximum assigned dosage of Diclectin or placebo tablets do not exceed 4 tablets per day. The treatment duration will lasts for 14 days.
Study NCT04401384 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Diclectin placebo
Description: Diclectin placebo will be packed and tested by a commercial pharmacy supply company specifically for this study. It have the same appearance, size, batch, odor, and taste compared with Diclectin. During the first two days, patients will start with an initial oral dose of 2 tablets at bedtime. If the symptoms assessed on the second day are not relieved, 3 tablets will be administered on the third day (1 tablet in the morning and 2 tablets at bedtime). On the third day if the symptoms are still not relieved, another tablet will be added in the afternoon on the fourth day (1 tablet in the morning, 1 tablet in the afternoon and 2 tablets at bedtime). Therefore, the maximum assigned dosage of placebo tablets do not exceed 4 tablets per day. The treatment duration will lasts for 14 days.
Study NCT04401384 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Active acupuncture
Description: Participants will receive active acupuncture every day for 2 consecutive weeks, a total of 14 sessions. The needle will be left for 30 minutes. After de qi induced by acupuncture, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6).
Study NCT04401384 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sham acupuncture
Description: Blunt-tipped placebo needles will be used. Participants will receive sham acupuncture every day for 2 consecutive weeks, a total of 14 sessions. The needle will be left for 30 minutes. After de qi induced by acupuncture, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6). Then, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6).
Study NCT02697253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin 9-39 and Sitagliptin
Description: Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours.
Study NCT02697253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~100mg Placebo tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg placebo tablet at 0700 hours.
Study NCT03924726 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Micro-osteoperforation (MOP)
Description: Micro-osteoperforation technique is used to accelerate orthodontic tooth movement.
Study NCT05086367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic and pursed lip breathing
Description: Breathing exercises were performed. Two breathing techniques were applied to the participants. Diaphragmatic and pursed lip breathing were intervened along with routine physical therapy.
Study NCT02958735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Challenge
Description: Participants randomized to an exercise condition will perform treadmill exercise for 30 minutes. Participants will self-select a comfortable walking speed. The treadmill grade will be adjusted to elicit and maintain the target heart rate.
Study NCT05086367 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy
Description: Routine physical therapy exercises were performed in which neck isometrics and neck range of motion exercises were performed
Study NCT04386330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distance-delivered NET
Description: One-on-one intervention delivered by a paraprofessional; 12 weekly videoconference sessions at 90 minutes.
Study NCT04282941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen in continuous (24 hours) iv infusion and EchoG
Description: The first dose of ibuprofen will be 10 mg / kg to be administered as a continuous infusion for 24 hours. An echocardiogram will be performed before each of the following 2 doses of 5 mg / Kg and will only be administered if it meets echocardiographic criteria that indicate open DA (observation of ductus permeability with color Doppler regardless of its size). Each dose will be administered as a 24-hour continuous infusion.
Study NCT01587651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel Loading Dose
Description: 60mg given as six 10mg film coated tablets
Study NCT01587651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel Maintenance Dose
Description: 10mg maintenance dose, given as one 10mg film coated tablet
Study NCT01587651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor Maintenance Dose
Description: one 90mg film coated tablet
Study NCT04282941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV bolus Ibuprofen slow (15 minutes) and EchoG
Description: The first dose of ibuprofen of 10 mg / Kg to be administered in slow iv bolus (15 minutes). Before each of the following 2 doses of 5 mg / Kg, echocardiography will be performed and will only be administered if it meets the echocardiographic criteria indicated by open DA (observation of ductus permeability in color Doppler regardless of its size). Each dose will be administered in iv boluses in 15 minutes
Study NCT03342638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Potent immunosuppressive agent; an alkylating agent
Study NCT03342638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
Study NCT03342638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rATG
Description: A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
Study NCT03342638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Steroid
Study NCT03342638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
Study NCT02875613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10mg/kg IV on days 1 and 15 of each 28-day cycle. Treatment will be given until disease progression, unacceptable toxicity, investigator decision or patient withdrawal.
Study NCT04740398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-1008
Description: CBP-1008 for injection; IV infusion; Infusion for 90 minutes
Study NCT03647618 — intervention group
Intervention type: OTHER
Intervention: Ultrasound
Description: Ultrasound-guided regional anaesthesia
Study NCT00992901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin-(9-39)
Description: A physiological study to evaluate the role of GLP-1 signaling in glucose tolerance and insulin secretion
Study NCT00992901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism
Study NCT00992901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 and GIP
Description: A physiological study to evaluate the beta-cell sensitivity to different doses of exogenous gut hormones
Study NCT00558701 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcurrent stimulator
Description: Microcurrent stimulation from 15-50 microamps
Study NCT00558701 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silverlon Wound Contact Dressing
Description: Silver coated nylon dressing FDA approved for use on donor sites in burn patients
Study NCT00558701 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Silverlon Wound Contact Dressing
Description: Silver coated nylon dressing FDA approved for use on donor sites in burn patients
Study NCT04067167 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: WB-EMS (Sham-intervention)
Description: Whole-Body Electromyostimulation (WB-EMS):~WB-EMS with low-threshold stimulation during a study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~* patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week
Study NCT04067167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WB-EMS
Description: Whole-Body Electromyostimulation (WB-EMS):~WB-EMS during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~* WB-EMS stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec;~* patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week
Study NCT04067167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free WB-EMS
Description: Whole-Body Electromyostimulation (WB-EMS) using a mobile system:~WB-EMS during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~* WB-EMS stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec;~* patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week
Study NCT04067167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexi band resistance training
Description: Flexi band resistance Training:~Training during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~* patients perform resistance exercises using flexi bands~* flexi band exercises are conceptualized to activate similar muscle groups as EMS exercise~* time-effort per session: \~20 min~* 2 training sessions per week
Study NCT04614935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Plan
Description: See arm description.
Study NCT01006187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal lidocaine
Description: 4% cream; approximately one gram applied to injection site under an occlusive dressing for 20 minutes prior to injection
Study NCT01006187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vapocoolant spray
Description: medium stream spray on arm for 4-10 seconds prior to injection
Study NCT01006187 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rubbing adjacent to the injection site
Description: rubbing adjacent to the injection site before and during injection
Study NCT01006187 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Distraction
Description: By means of self-selected reading material or video